CASI Stock Analysis: Buy, Sell, or Hold?
CASI - CASI Pharmaceuticals, Inc. Ordinary Shares
$0.21
-0.59 (-74.06%)
▼
5d:
-73.37%
30d:
-78.83%
90d:
-83.13%
WAIT
LOW Confidence
Analysis Updated: Feb 25, 2026 12:00 AM ET
Earnings: Mar 30, 2026
0d
Get Alerted When CASI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CASI is down 73.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CASI is down 73.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CASI is currently trading at $0.21, which is considered fair based on recent price action.
Technical Outlook: Technically, CASI is in a strong downtrend. The price is currently testing key support at $0.21. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 74.1% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $4.00 (+1827.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CASI is in a strong downtrend. The price is currently testing key support at $0.21. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 74.1% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $4.00 (+1827.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
42/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
64.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BEARISH: Downward momentum (-74.1%)
- BULLISH: Trading 1827.7% below Wall St target ($4.00)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Support & Resistance Levels
Support Level
$0.21
Resistance Level
$0.97
Current Trend
Strong Downtrend
Technical data as of
Feb 25, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.15
Wall Street Target
$4.00
(+1827.7%)
Revenue Growth (YoY)
-60.5%
Profit Margin
-184.0%
Share & Embed Analysis
Last updated: August 09, 2026 5:24 AM ET
Data refreshes hourly during market hours. Next update: 6:24 AM
Data refreshes hourly during market hours. Next update: 6:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CASI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 47 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 64 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 35 SELL |
